LY4066434

· Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for LY4066434, covering 2026-04-22 to 2026-04-22. Get the full timeline:

Most recent: Clinical Trial Update: A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors [Phase 1]